SAN
DIEGO, July 11, 2023 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) today announced that it appointed
Christine A. Poon, a business leader
with extensive experience in the pharmaceutical industry, to its
Board of Directors.
"Christine Poon brings a wealth
of industry experience to Neurocrine's Board of Directors," said
William H. Rastetter, Chairman of
the Board of Neurocrine Biosciences. "Her strong track record in
leadership positions at some of the most established global
biopharmaceutical enterprises will serve Neurocrine well."
Ms. Poon has demonstrated broad expertise in pharmaceutical
operations, including capital allocation decisions, during a
30-year career in the healthcare industry. She served as Vice
Chairman and Member of the Board of Directors of Johnson &
Johnson from 2005 until her retirement in March 2009. Ms. Poon joined Johnson & Johnson
in 2000 as Company Group Chair in the Pharmaceuticals Group. She
became a member of the company's Executive Committee and Worldwide
Chair, Pharmaceuticals Group, in 2001, and served as Worldwide
Chair, Medicines and Nutritionals, from 2003 to 2005.
After her retirement from Johnson & Johnson, she served at
the Max M. Fisher College of Business
at The Ohio State University as Dean
and the John W. Berry, Sr. Chair in Business from 2009 to 2014, and
as Executive-in-Residence in the Department of Management and Human
Resources from 2015 to 2020.
Prior to joining Johnson & Johnson, she spent 15 years at
Bristol-Myers Squibb in various management positions. Ms. Poon is
on the Board of Directors of Prudential Financial, Inc., The
Sherwin-Williams Company, and is the lead independent director of
Regeneron Pharmaceuticals, Inc. She was named Woman of the Year by
the Healthcare Businesswomen's Association in 2004 and named
Business Leader of the Future by CNBC/Wall Street Journal in
2005.
About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused,
biopharmaceutical company with a simple purpose: to relieve
suffering for people with great needs, but few options. We are
dedicated to discovering and developing life-changing treatments
for patients with under-addressed neurological, neuroendocrine, and
neuropsychiatric disorders. The company's diverse portfolio
includes FDA-approved treatments for tardive dyskinesia,
Parkinson's disease, endometriosis* and uterine fibroids*, as well
as a robust pipeline including multiple compounds in mid- to
late-phase clinical development across our core therapeutic areas.
For three decades, we have applied our unique insight into
neuroscience and the interconnections between brain and body
systems to treat complex conditions. We relentlessly pursue
medicines to ease the burden of debilitating diseases and
disorders, because you deserve brave science. For more information,
visit neurocrine.com, and follow the company on LinkedIn,
Twitter and Facebook. (*in collaboration with AbbVie)
Forward-Looking Statements
In addition to historical facts, this press release contains
forward-looking statements that involve a number of risks and
uncertainties. Among the factors that could cause actual results to
differ materially from those indicated in the forward-looking
statements are those risks described in our periodic reports filed
with the SEC, including without limitation our quarterly report on
Form 10-Q for the quarter ended March 31,
2023. Neurocrine Biosciences disclaims any obligation to
update the statements contained in this press release after the
date hereof.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-appointment-of-christine-a-poon-to-board-of-directors-301874728.html
SOURCE Neurocrine Biosciences, Inc.